FGFR Pathway Mutation PCR Array
|qBiomarker Somatic Mutation PCR Array: Human FGFR Pathway
|The fibroblast growth factor receptors (FGFRs) are receptors that bind fibroblast growth factors (FGFs), members of
the largest family of growth factor ligands. The FGFRs and their downstream signaling cascades have been
implicated in a diverse range of cellular processes including proliferation, apoptosis, survival, chemotaxis, cell
adhesion, and differentiation. The importance of proper FGFR signaling is evident from genetic studies in human and
mouse models demonstrating disruption of FGF signaling by mutations cause a variety of disorders including skeletal
diseases, infertility, and cancer.
The Human FGFR Pathway qBiomarker Somatic Mutation PCR Array is a translational research tool that allows
rapid and accurate profiling of the somatic mutation status of FGFR genes and key genes in the FGFR signaling
pathways: AKT, BRAF, KRAS, HRAS, NRAS, MEK1, PIK3CA, and PTEN. The utility of individual and multiple
somatic mutation status information in identifying key signaling transduction disruptions has been demonstrated in
numerous research studies. For example, the mutation status of the EGFR and KRAS genes can predict the
physiological response to certain drugs targeting these molecules. The FGFR Pathway qBiomarker Somatic
Mutation PCR Array, with its comprehensive content coverage, is designed for studying mutations in the context of
the FGFR pathway and has the potential for discovering drug target biomarkers for a variety of human diseases
involving the FGFR signaling pathway and downstream effectors. This array covers 85 DNA sequence mutation
assays designed to detect the most frequent, functionally verified, and biologically most significant mutations in the
FGFR pathways. These mutations were chosen from curated, comprehensive somatic mutation databases and peerreviewed
scientific literature. The simplicity of the product format and operating procedure allows routine somatic
mutation profiling in any research laboratory with access to real-time PCR instruments.
The qBiomarker Somatic Mutation PCR Arrays are intended for molecular biology applications. This product is not
intended for the diagnosis, prevention, or treatment of a disease.
| Modify this Array
FGFR genes (FGFR1, FGFR2, FGFR3):
15 mutation assays are included for FGFR1, 2 and 3 in this panel. These assays detect the most frequently identified
kinase domain mutations and non-kinase domain (e.g. extracellular domains such as the hinge region and IgG-like
domain) mutations. Some of the somatic mutations included have congenital correlates that are involved in genetic
The mutation assay detects the best known AKT1 mutation, c.49G>A, p.E17K. This is a PH domain mutation that
results in constitutive targeting of AKT1 to plasma membrane.
Two classes of mutation assays are included. One class covers mutations that lead to increased BRAF kinase
activity, such as the p.V600 mutations. The other class detects mutations that lead to impaired kinase activity, such
as the p.G464V, p.G466V, and p.G469A mutations.
16 KRAS mutation assays provide comprehensive analysis capacity for the most frequently occurring mutations in
KRAS codon positions 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or
cause KRAS to become unresponsive to RasGAP. The p.Q22K mutation assay is also included.
Similar to KRAS mutation assays, the 13 HRAS mutation assays on this panel aim to cover the most important
HRAS mutations identified in cancers at codon 12, 13, and 61 positions.
12 NRAS mutation assays are included on the panel to cover codon positions 12, 13, and 61.
4 assays for mutations with significance in cancer were included on this panel. These mutations cluster in MEK1 Nterminal negative regulatory domain and an adjacent domain, and are all activating mutations (i.e. lead to upregulated intrinsic MEK1 kinase activity).
PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) gene:
The mutation assays covered on this panel can detect 7 of the most frequently occurring PIK3CA mutations that
belong to two classes: p.H1047 mutations, which are activating, kinase domain mutations; and mutations in P539-
E545 region, which are helical domain mutations that mimic activation by growth factors.
Included on the panel are 6 most commonly detected PTEN loss-of-function mutations that are due to either
truncation (p.R233* and p.R130*) or point mutation-caused phosphatase inactivation (p.R130 and p.R173
Overview of the qBiomarker Somatic
Mutation PCR Array / Assay Protocol
Overview of the qBiomarker Somatic Mutation PCR Array / Assay
The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue
Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g
UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR
detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis
(using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA
sample QC step immediately before the detection array or assay setup allows the
user to qualify the DNA samples.
Principle of Mutant Discrimination with ARMS®
Back to Top
- Potential for Targeting the Fibroblast Growth Factor Receptors in Breast Cancer. Hynes NE, Dey JH Cancer Research 2010 Jul; 70; 5199
- The PKB/AKT pathway in cancer. Carnero A. Curr Pharm Des. 2010 Jan; 16(1):34-44.
- BRAF, a target in melanoma: implications for solid tumor drug development. Flaherty KT, McArthur G. Cancer. 2010 Jul 13. [Epub ahead of print].
- Clinical relevance of KRAS in human cancers. Jancík S, Drábek J, Radzioch D, Hajdúch M. J Biomed Biotechnol. 2010; 2010:150960.
- Oncogenic Ras in tumour progression and metastasis. Giehl K. Biol Chem. 2005 Mar; 386(3):193-205.
- MEK1 mutations confer resistance to MEK and B-RAF inhibition. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA. Proc Natl Acad Sci U S A. 2009 Dec 1; 106(48):20411-6.
- PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M. Cell Cycle. 2009 May 1; 8(9):1352-8.
- Oncogenic mutations as predictive factors in colorectal cancer. Ličvre A, Blons H, Laurent-Puig P. Oncogene. 2010 May 27; 29(21):3033-43.
- PI(3)King Apart PTEN's Role in Cancer. Zhang S, Yu D. Clin Cancer Res. 2010 Jul 8. [Epub ahead of print].